Agenus Inc (OQ:AGEN)

Business Focus: Biotechnology & Medical Research

Oct 22, 2021 08:00 am ET
Agenus Provides Update on Balstilimab Development
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced a strategic decision to...
Oct 12, 2021 08:30 am ET
Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the...
Oct 01, 2021 08:00 am ET
Agenus to Present AGEN1181 Clinical Data at SITC
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its...
Sep 16, 2021 06:25 pm ET
Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the...
Sep 10, 2021 07:30 am ET
New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections today announced the launch of SaponiQx, a...
Sep 09, 2021 08:00 am ET
Agenus to Participate in September Investor Conferences
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD,...
Aug 26, 2021 09:00 am ET
Balstilimab Monotherapy Data Published in Gynecologic Oncology
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a...
Aug 09, 2021 07:45 am ET
Agenus Corporate Update and Second Quarter 2021 Financial Report
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update...
Aug 02, 2021 04:05 pm ET
Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD,...
Jul 28, 2021 08:30 am ET
MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The...
Jul 26, 2021 04:05 pm ET
Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its...
Jul 07, 2021 04:05 pm ET
Agenus to Participate in Resistance-Focused Oncology Panel at the William Blair Biotech Focus Conference 2021
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O’Day, MD,...
Jul 06, 2021 08:30 am ET
Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today...
Jun 21, 2021 09:00 am ET
Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD,...
Jun 17, 2021 08:30 am ET
Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today...
Jun 15, 2021 08:30 am ET
Agenus Announces Virtual Annual Shareholders Meeting
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that its annual meeting...
Jun 04, 2021 09:09 am ET
Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the...
Jun 01, 2021 04:05 pm ET
Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD,...
May 20, 2021 07:00 am ET
Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced data on the...
May 18, 2021 07:31 am ET
Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives...
May 18, 2021 07:30 am ET
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc
May 18, 2021 07:30 am ET
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific...
May 06, 2021 07:45 am ET
Agenus Corporate Update and First Quarter 2021 Financial Report
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update...
Apr 28, 2021 05:30 pm ET
Agenus to Present at the 2021 ASCO Annual Meeting
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two...
Apr 22, 2021 04:05 pm ET
Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its...
Apr 19, 2021 08:30 am ET
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today...
Apr 14, 2021 08:30 am ET
Agenus Doses First Cancer Patient with iNKT Cell Therapy
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the dosing of the...
Apr 10, 2021 08:35 am ET
New Clinical Responses for AGEN1181 Presented at AACR
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented new clinical data on...
Apr 06, 2021 08:30 am ET
Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell,...
Mar 15, 2021 07:45 am ET
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update...
Mar 10, 2021 04:32 pm ET
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that two abstracts...
Mar 02, 2021 08:30 am ET
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its...
Feb 09, 2021 05:06 pm ET
Andy Hurley Named Agenus Chief Commercial Officer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of...
Feb 09, 2021 11:00 am ET
Agenus Announces Agenus Insights - Virtual R&D Miniseries
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host...
Feb 09, 2021 08:45 am ET
Agenus Announces New Responses for AGEN1181
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed...
Feb 04, 2021 08:31 am ET
Thinking about buying stock in Canopy Growth Corp, 3D Systems, Bilibili, Agenus, or Vyne Therapeutics?
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, DDD, BILI, AGEN, and VYNE.
Feb 04, 2021 08:30 am ET
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced positive preliminary...
Jan 26, 2021 08:30 am ET
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it has entered...
Jan 19, 2021 12:09 pm ET
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer...
Dec 03, 2020 07:45 am ET
Completion of Balstilimab BLA Filing Extended To 1H2021
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced updated...
Dec 01, 2020 08:00 am ET
Agenus Launches Phase 2 Trial Expansion in Colon Cancer for AGEN1181 in Combination with Balstilimab
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the expansion...
Nov 25, 2020 01:28 pm ET
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer...
Nov 16, 2020 07:04 pm ET
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer...
Nov 13, 2020 02:42 pm ET
Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven...
Nov 12, 2020 09:00 am ET
Agenus and Dr. Steven O’Day to Participate in Panels at the Virtual SITC 2020 Immuno-Oncology Event Hosted by B. Riley
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Steven...
Nov 11, 2020 07:30 am ET
XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ: AGEN) related to Merck’s advancement of MK-4830 into a Phase 2 study in patients with advanced...
Nov 10, 2020 08:45 am ET
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that a milestone...
Nov 09, 2020 08:15 am ET
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced presentations on...
Nov 05, 2020 08:00 am ET
Dr. Steven O’Day Named Agenus Chief Medical Officer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of...
Nov 02, 2020 08:45 am ET
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic...
Oct 29, 2020 07:45 am ET
Agenus R&D Update & Third Quarter Financial Report
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a...
Oct 20, 2020 10:34 am ET
Agenus to Report Third Quarter Earnings
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its...
Oct 14, 2020 05:00 pm ET
Agenus to Present on Seven Novel Programs at SITC 2020
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that seven abstracts...
Oct 13, 2020 08:30 am ET
Susan Hirsch Joins Agenus’ Board of Directors
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms....
Sep 18, 2020 08:30 am ET
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of the...
Sep 18, 2020 03:00 am ET
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented preliminary results...
Sep 17, 2020 05:06 pm ET
Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer...
Sep 17, 2020 01:38 pm ET
Agenus to Participate in Webcast Hosted by William Blair on ESMO2020 Results and Novel Pipeline
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. David...
Aug 06, 2020 07:30 am ET
Agenus Provides R&D Update & Second Quarter Financial Report
LEXINGTON, Mass., Aug. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided an R&D and business update and reported financial results for the second quarter of 2020.
Aug 04, 2020 08:30 am ET
Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference
LEXINGTON, Mass., Aug. 4, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced today that Dr. Jennifer Buell, President and COO of Agenus will present on Targeting Myeloid Cells in the Tumor Microenvironment at the upcoming William Blair Biotech Focus Conference 2020.
Jul 29, 2020 02:00 pm ET
Agenus R&D update & Second Quarter Earnings Report
LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020. Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.
Jul 28, 2020 11:23 am ET
Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals
LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, today announced the closing of a $20 million equity investment, at $4.03 per share, by Betta Pharmaceuticals (SZ300558) bringing the total received to $35M. Betta is a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies.  The equity investment by Betta Pharmaceuticals is part of the broader immuno-oncology (I-O) partnership that Agenus and Betta Pharmaceuti
Jul 21, 2020 01:31 pm ET
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit
LEXINGTON, Mass., July 21, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit – Thera
Jun 22, 2020 09:43 am ET
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
LEXINGTON, Mass., June 22, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that it will make a scientific presentation today on optimal anti-cancer combinations with Fc enhanced anti-CTLA-4, AGEN1181, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting.
Jun 22, 2020 09:31 am ET
Thinking about buying stock in Virgin Galactic, Miragen Therapeutics, Nantkwest Inc, Agenus Inc, or Norwegian Cruise Line?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, MGEN, NK, AGEN, and NCLH.
Jun 22, 2020 07:00 am ET
Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China
LEXINGTON, Mass., June 22, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with an extensive pipeline of agents designed to activate immune response to cancers, announced today that it has entered into an agreement with Betta Pharmaceuticals (SZ300558), a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies, for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.
Jun 17, 2020 11:06 am ET
Agenus and AgenTus to Participate in a Panel Presentation on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, Chief Technology Officer of Agenus and AgenTus Therapeutics, will participate in a panel discussion on Cell Therapy at the Raymond James Virtual Human Health Innovation Conference on June 17, 2020.
Jun 17, 2020 10:53 am ET
Agenus to Present at the Raymond James Virtual Human Health Innovation Conference
LEXINGTON, Mass., June 17, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus' progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020.
Jun 16, 2020 08:12 am ET
Agenus Announces Virtual Annual Shareholders Meeting
LEXINGTON, Mass., June 16, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announces that it will host its 2020 Annual Shareholders Meeting virtually due to public health concerns related to the COVID-19.
Jun 02, 2020 08:30 am ET
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients
LEXINGTON, Mass., June 2, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced today the FDA's clearance of AgenTus' IND application for an allogeneic iNKT therapy. AgenT-797 was submitted by AgenTus Therapeutics, a subsidiary of Agenus. A clinical trial for the treatment of patients with COVID-19 is expected to commence shortly. Agenus previously reported the FDA clearance of the IND for the use of allogeneic iNKTs for patients with cancer.
Jun 01, 2020 09:31 am ET
Thinking about buying stock in General Electric, Zynga Inc, Tilray, Agenus Inc, or Walmart?
NEW YORK, June 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GE, ZNGA, TLRY, AGEN, and WMT.
May 29, 2020 08:00 am ET
ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day
LEXINGTON, Mass., May 29, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced the American Society of Clinical Oncology (ASCO2020) Virtual Scientific Program on AGEN1181 by Dr. Steven J. O'Day, the Executive Director of the John Wayne Cancer Institute and Cancer Clinic and Director of Providence Los Angeles Regional Research. 
May 14, 2020 08:00 am ET
Agenus NextGen CTLA-4 Antibody (AGEN1181) Data to be Presented at ASCO
LEXINGTON, Mass., May 14, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced today that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020.
May 13, 2020 09:54 am ET
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
LEXINGTON, Mass., May 13, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infectious diseases, announced today the FDA acceptance of the IND application for an allogeneic iNKT therapy, agenT-797, submitted by its subsidiary, AgenTus Therapeutics. A clinical trial for the treatment of patients with cancer is expected to commence 2H2020. AgenTus has also submitted a separate IND for the treatment of COVID-19, which is expected to clear soon.
May 07, 2020 08:00 am ET
Agenus First Quarter Results and Update
LEXINGTON, Mass., May 7, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and reported financial results for the first quarter of 2020.
Apr 28, 2020 11:50 am ET
Agenus to Report First Quarter 2020 Financial Results on May 7, 2020 and Host Conference Call and Webcast
LEXINGTON, Mass., April 28, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, will release its first quarter 2020 financial results before the market opens on Thursday, May 7, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and provide a business update.
Apr 07, 2020 01:04 pm ET
Agenus Receives Fast Track Designation for Balstilimab in Advanced Cervical Cancer
LEXINGTON, Mass., April 7, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab (anti-PD-1) for the treatment of cervical cancer. This designation was based on comprehensive data that support the potential for balstilimab to address a significant unmet medical need. Agenus expects to file 2 BLAs this year for accelerated approval of the combinatio
Nov 12, 2019 11:48 am ET
Agenus to Host R&D Day November 15, 2019
LEXINGTON, Mass., Nov. 12, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.
Nov 11, 2019 07:00 am ET
Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment of urinary tract cancers
LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that it received $10M upfront for a License Agreement with UroGen Pharma Ltd. Under the agreement Agenus is providing access to zalifrelimab (AGEN1884, anti-CTLA-4 antibody) for use with UroGen's sustained release technology for intravesical delivery in patients with urinary tract cancers.  Agenus is conducting clinical trials for zalifrelimab in combination with Agenus' anti
Nov 04, 2019 06:00 am ET
Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.
Oct 31, 2019 12:04 pm ET
Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and provide a business update.
Sep 30, 2019 04:34 pm ET
Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
LEXINGTON, Mass., Sept. 30, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that Jennifer Buell, PhD, Chief Operating Officer of Agenus, present an update on Agenus' progress and host one-on-one meetings with investors at the 2019 Cantor Global Healthcare Conference on October 4th, 2019 at the InterContinental New York Barclay Hotel.
Aug 08, 2019 07:30 am ET
Agenus Milestone Triggers $7.5M Payment
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments this year and beyond.
Aug 08, 2019 07:30 am ET
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported financial results for the second quarter of 2019.
Aug 06, 2019 10:56 am ET
Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day.
Jul 18, 2019 02:00 pm ET
Agenus Appoints Don Vidic as Vice President and Head of Commercial
LEXINGTON, Mass., July 18, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial.
May 09, 2019 07:30 am ET
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
LEXINGTON, Mass., May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported financial results for the first quarter of 2019.
May 03, 2019 01:38 pm ET
Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its first quarter 2019 financial results before the market opens on Thursday, May 9, 2019. In connection with the earnings release, Agenus executives will host a conference call and live webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.
Apr 10, 2019 08:55 am ET
Detailed Research: Economic Perspectives on Agenus, Warrior Met Coal, Cubic, Nielsen Holdings Plc, Leidos, and Limoneira — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Agenus Inc. (NASDAQ:AGEN), Warrior Met Coal Inc. (NYSE:HCC), Cubic Corporation...
Apr 02, 2019 08:30 am ET
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells.
Mar 21, 2019 09:00 am ET
Agenus Announces Clinical Appointments
LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020.
Mar 14, 2019 08:00 am ET
Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass., March 14, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the fourth quarter and full year of 2018.
Mar 13, 2019 08:30 am ET
Agenus Milestone Triggers $7.5M Payment from Gilead
LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments in 2019 and beyond.
Mar 08, 2019 08:00 am ET
Agenus to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., March 8, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, March 14, 2019. In connection with the earnings release, Agenus executives will host a conference call and live webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.
Feb 20, 2019 08:30 am ET
Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Caterpillar Inc. (NYSE:CAT), Agenus Inc....
Feb 19, 2019 07:30 am ET
Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare
LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare.
Feb 15, 2019 10:41 am ET
Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019
LEXINGTON, Mass., Feb. 15, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare, will be launched on February 19, 2019.
Jan 29, 2019 07:00 am ET
Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare
LEXINGTON, Mass., Jan. 29, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare.  Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity.
Jan 29, 2019 07:00 am ET
Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.
NEW YORK, Jan. 29, 2019 /PRNewswire/ -- At a gathering of institutional investors this morning, Atomic Capital and Agenus Inc (NASDAQ: AGEN), announced the  launch of a groundbreaking digital securities offering enabling the direct participation of accredited investors in Agenus' lead immuno-oncology asset. The proceeds from the digital securities offering, the first conducted by a publicly-traded company, will go to fund product development through FDA approval and commercialization, of the asset, with returns to investors backed by future product sales.
Jan 24, 2019 07:30 am ET
Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead Sciences, Inc. (NASDAQ: GILD), focused on the development and commercialization of up to five novel immuno-oncology therapies.
Jan 09, 2019 07:30 am ET
Research Report Identifies Conagra Brands, W.R. Grace, International Flavors & Fragrances, Spirit Airlines, Sunstone Hotel Investors, and Agenus with Renewed Outlook — Fundamental Analysis, Calculatin
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (NYSE:CAG), W.R. Grace & Co. (NYSE:GRA),...
Jan 03, 2019 10:30 am ET
Agenus Awarded Grant to Enable QS-21 Innovations
LEXINGTON, Mass., Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill & Melinda Gates Foundation awarded it a grant of ~$1M to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of Agenus' proprietary QS-21 Stimulon® adjuvant, a key component of multiple vaccines targeting infectious and endemic diseases.
Dec 21, 2018 08:31 am ET
Thinking about buying stock in Agenus Inc., BlackBerry Limited, Caesars Entertainment Corp., New Age Beverages Corp., or Twitter, Inc.?
NEW YORK, Dec. 21, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGEN, BB, CZR, NBEV, and TWTR.
Dec 20, 2018 07:23 am ET
Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.
Dec 20, 2018 06:30 am ET
Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.
Dec 04, 2018 12:00 pm ET
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief...
Nov 13, 2018 03:05 pm ET
Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell
LEXINGTON, Mass., Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of Directors and the appointment of Dr. Jennifer S. Buell to Chief Operating Officer.   
Nov 13, 2018 10:30 am ET
Agenus to Present at the 2018 Jefferies London Healthcare Conference
LEXINGTON, Mass., Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Jefferies London Healthcare Conference in London, UK.
Nov 09, 2018 07:55 am ET
Report: Developing Opportunities within Agenus, Kirkland's, Preferred Apartment Communities, Gulfport Energy, ProAssurance, and US Ecology — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agenus Inc. (NASDAQ:AGEN), Kirkland's, Inc. (NASDAQ:KIRK), Preferred...
Nov 06, 2018 04:42 pm ET
Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018
LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new data on several of its programs – including AutoSynVax™ (ASV™), discovery of a novel vaccine candidate for CRC and pre-clinical data on a novel anti-CD137 antibody – at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting in Washington, D.C. November 7-11. 
Nov 06, 2018 06:30 am ET
Agenus Reports Third Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Nov. 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the third quarter of 2018.
Oct 31, 2018 09:23 am ET
Agenus to Report Third Quarter 2018 Financial Results on November 6, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass., Oct. 31, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its third quarter 2018 financial results before the market opens on Tuesday, November 6, 2018. In connection with the earnings release, Agenus executives will host a conference call and live audio webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.
Oct 20, 2018 07:30 am ET
Agenus Presents Clinical Data on Its PD-1 & CTLA-4 at ESMO 2018
LEXINGTON, Mass., Oct. 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies2, presented updated clinical data on its lead CTLA-4 and PD-1 programs today at the 2018 European Society for Medical Oncology (ESMO) Congress, in Munich, Germany.
Oct 09, 2018 09:00 am ET
Agenus To Present Data on Proprietary CTLA-4 & PD-1 Antibodies at ESMO 2018
LEXINGTON, Mass., Oct. 9, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new clinical data on its lead CTLA-4 and PD-1 programs at the European Society for Medical Oncology (ESMO) Congress in Munich this month. 
Oct 08, 2018 08:25 am ET
Recent Analysis Shows Ryman Hospitality Properties, PennantPark Investment, PS Business Parks, Agenus, Belden, and Robert Half International Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ryman Hospitality Properties, Inc. (NYSE:RHP), PennantPark Investment...
Sep 28, 2018 08:38 am ET
Agenus to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York, NY
LEXINGTON, Mass., Sept. 28, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Cantor Fitzgerald Global Healthcare Conference at the Intercontinental NY Barclay Hotel.
Sep 21, 2018 07:00 am ET
Agenus Closes $15 Million Partial Royalty Monetization With XOMA
LEXINGTON, Mass., Sept. 21, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation (XOMA), where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck. Agenus received $15.0 million at closing and retains the majority (67%) of all future royalties and 90% of all milestones from Incyte and Merck. Agenus also remains elig
Sep 17, 2018 09:00 am ET
Agenus Receives Milestone Payment from Incyte
LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Based on this milestone and under the terms of the agreement, Agenus received a $5 million payment and is eligible to receive up to an additional $505 million in potential development, regulatory and commercial milestones from Inc
Sep 05, 2018 07:34 pm ET
AgenTus Therapeutics to Present on the Anti-tumor Activities of Two Proprietary T Cell Receptors (TCRs) at CAR-TCR Summit in Boston, MA
LEXINGTON, Mass., Sept. 5, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa, Senior Director, Molecular Biology, AgenTus Therapeutics will present at the CAR-TCR Summit in Boston on September 6, 2018.
Sep 04, 2018 09:57 am ET
Agenus to Present at The Annual B. Riley FBR Healthcare Conference in New York City
LEXINGTON, Mass., Sept. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus and Robert Stein, MD, PhD, Senior R&D Advisor at Agenus, will make a presentations and host one-on-one meetings with investors at the 2018 Annual B. Riley FBR Healthcare Conference, at NY Marriott East Side in New York City.
Aug 15, 2018 01:22 pm ET
Agenus Receives Second Milestone Payment from Merck
LEXINGTON, Mass., Aug. 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that Merck, known as MSD outside the United States and Canada, initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. Based on this milestone and under the terms of the agreement, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 m
Aug 09, 2018 08:00 am ET
Agenus Reports Second Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Aug. 9, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the second quarter of 2018.
Aug 02, 2018 02:00 pm ET
Agenus to Report Second Quarter 2018 Financial Results on August 9, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass., Aug. 2, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its second quarter 2018 financial results before the market opens on Thursday, August 9, 2018. In connection with the earnings release, Agenus executives will host a conference call and live audio webcast at 8:30 a.m. ET the same day to discuss the results and provide Company updates.
Jul 27, 2018 07:45 am ET
New Research: Key Drivers of Growth for Cadence Design, Agenus, Foundation Medicine, Honeywell International, NeoPhotonics, and Citrix — Factors of Influence, Major Initiatives and Sustained Productio
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cadence Design Systems, Inc. (NASDAQ:CDNS), Agenus Inc. (NASDAQ:AGEN),...
Jul 16, 2018 08:37 am ET
Agenus Appoints Regulatory and Clinical Heads
LEXINGTON, Mass., July 16, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1, today announced the appointment of I-O drug development experts into key leadership positions.  These appointments will help advance multiple clinical programs and planned BLA filings by 2020.
Jun 20, 2018 08:00 am ET
Agenus to Webcast Annual Meeting of Stockholders
LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1 invites investors and the general public to attend its Annual Meeting of Stockholders to begin at 5:00 p.m. ET today, Wednesday, June 20, 2018. The meeting is being held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
Jun 12, 2018 08:30 am ET
Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell
LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (NASDAQ: AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4.  Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018.
Jun 06, 2018 01:00 pm ET
Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY
LEXINGTON, Mass., June 6, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the Jefferies 2018 Global Healthcare Conference at the Grand Hyatt Hotel, New York, NY. 
May 17, 2018 01:37 pm ET
Agenus to Present Clinical Data on Lead Programs at ASCO 2018
LEXINGTON, Mass., May 17, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced that data on its proprietary AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) antibodies have shown consistent clinical activity with a number of partial responses, stable disease and currently, one complete responder.  Updated data on these agents will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago June 1-5. Agenus recently announced the
May 07, 2018 01:00 pm ET
Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston
LEXINGTON, Mass., May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Garo Armen, Ph.D., Chairman & CEO, and Jennifer Buell, Ph.D., Chief External Affairs and Communications Officer at Agenus, will make a presentation and host one-on one meetings with investors at Deutsche Bank's 43rd Annual Health Care Conference at the InterContinental Boston Hotel on Tuesday, May 8, 2018. Details of the company's presentation and a live webcast are provide
May 07, 2018 09:00 am ET
Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update
LEXINGTON, Mass., May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the first quarter ending March 31, 2018.
May 03, 2018 09:00 am ET
Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass., May 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its first quarter 2018 financial results before the market opens on Monday, May 07, 2018. In connection with the earnings release, Agenus executives will host a conference call and live audio webcast at 11:00 a.m. ET the same day to discuss the results and provide Company updates.
May 01, 2018 08:00 am ET
AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA
LEXINGTON, Mass., May 1, 2018 /PRNewswire/ -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Andy Hurwitz, Vice President, Head of Preclinical Research, AgenTus Therapeutics will present at the PEGS Summit in Boston on May 2, 2018.
Apr 11, 2018 10:00 am ET
Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting
LEXINGTON, Mass., April 11, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that three abstracts were accepted for presentation at the AACR 2018 Annual Meeting in Chicago from April 14-18, 2018.
Mar 29, 2018 08:30 am ET
Agenus to Present at Healthcare Investor Conferences In April
LEXINGTON, Mass., March 29, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's leadership will present and host one-on-one meetings at two healthcare investment conferences in April. The details for the conferences are:
Mar 15, 2018 08:30 am ET
Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass., March 15, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for fourth quarter and full year 2017.
Mar 07, 2018 07:00 am ET
Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast
LEXINGTON, Mass., March 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018. In connection with the earnings release, Agenus executives will host a conference call and live audio webcast at 11:00 a.m. ET the same day to discuss the results and provide a company update.
Feb 21, 2018 08:00 am ET
New Research Coverage Highlights Acacia Research, Zebra Technologies, VSE, Spectrum Pharmaceuticals, Agenus, and Williams Companies — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acacia Research Corporation (NASDAQ:ACTG), Zebra Technologies...
Jan 22, 2018 09:00 am ET
Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of its combination trial with its proprietary anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. This Phase 1/2 clinical trial launched in December 2017 and enrollment into the first cohort has been rapidly completed.
Jan 22, 2018 06:00 am ET
Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners
LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the closing of its $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The transaction is comprised of approximately $190 million of cash proceeds at closing plus up to approximately $40 million in milestone payments. Agenus used part of the closing proceeds to redeem its royalty bond from Oberland in full, and the remainder will be used to advance its registrational studie
Jan 08, 2018 07:32 am ET
Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners
LEXINGTON, Mass., Jan. 8, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR). The transaction is comprised of $190 million of cash proceeds at closing plus up to $40 million in milestone payments. Agenus will use part of these proceeds to redeem its royalty bond from Oberland and the additional monies to advance its registrational studies with anti-CTLA-4 and anti-PD-1 for planned BLA filings in 20
Jan 04, 2018 06:30 am ET
Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018
LEXINGTON, Mass., Jan. 4, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Dr. John Castle, Head of Translational Medicine and Bioinformatics, will participate in a panel entitled "IO on the Move: New Targets, New Trends, New Combinations" on Wednesday, January 10,, 2018 at 9:00-10:00 am P.T. at the 10th Annual Biotech Showcase™ at the Hilton San Francisco Union Square.
Jan 03, 2018 06:00 am ET
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
LEXINGTON, Mass., Jan. 3, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced new leadership appointments to enhance its team and advance combination clinical programs which will support its planned BLA filings in the second half of 2019 and in 2020. 
Dec 05, 2017 07:30 am ET
Investor Expectations to Drive Momentum within Spectrum Pharmaceuticals, Agenus, Williams Companies, Acacia Research, Zebra Technologies, and Diodes — Discovering Underlying Factors of Influence
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Agenus Inc....
Nov 15, 2017 09:25 am ET
Agenus Receives License Fee of $4 Million USD from Merck
LEXINGTON, Mass., Nov. 15, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody under the license and research collaboration agreement with Merck, known as MSD outside the United States and Canada.
Nov 09, 2017 08:45 am ET
Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017
LEXINGTON, Mass., Nov. 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data on AGEN1884 (CTLA-4) and AGEN2034 (PD-1) demonstrated that the molecules achieved the desired pharmacologic function and combination synergy will be presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting, Nov. 9-13th.  Agenus recently announced the launch of three clinical programs with these lead antibodies designed as potential pivotal programs to support BLA filings as
Nov 08, 2017 02:12 pm ET
Agenus to Present at the Jefferies Global Healthcare Conference in London
LEXINGTON, Mass., Nov. 8, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer at Agenus, and Michael Plater, Ph.D., Chief Business Officer, Agenus, will make a presentation and host one-on one meetings with investors at the Jefferies Global Healthcare Conference at the Waldorf Hilton in London, U.K. on Wednesday, November 15, 2017.  The Company's presentation will take place at 8:00 a.m. GMT.
Nov 07, 2017 09:22 am ET
Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the third quarter ended September 30, 2017.
Nov 07, 2017 07:50 am ET
New Research: Key Drivers of Growth for Coty, Bristol-Myers Squibb, Carnival, Agenus, Steel Dynamics, and Impax Labs - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Ini
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coty Inc. (NYSE:COTY), Bristol-Myers Squibb Company...
Oct 26, 2017 01:40 pm ET
Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast
LEXINGTON, Mass., Oct. 26, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2017 financial results before the market opens on Tuesday, November 7, 2017. Agenus executives will host a conference call and webcast at 11:00 a.m. ET the same day.
Oct 25, 2017 05:24 pm ET
Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles
LEXINGTON, Mass., Oct. 25, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of three recommendations for the use of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) containing QS-21 Stimulon® for the prevention of shingles (herpes zoster):
Oct 23, 2017 12:26 pm ET
Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus
LEXINGTON, Mass., Oct. 23, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN) Chairman and Chief Executive Officer (CEO) Garo Armen Ph.D. announces the appointment of Bruno Lucidi as CEO of AgenTus Therapeutics, Inc., a subsidiary of Agenus that has been established as a dedicated cell therapy company, which will focus on the discovery, development, and commercialization of Adoptive Cell Therapy (ACT). Lucidi brings extensive expertise in drug development and more than 30 years of experience in the biopharmaceutical industry.
Oct 23, 2017 09:03 am ET
Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics
LEXINGTON, Mass., Oct. 23, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of a subsidiary company for its cell therapy business, AgenTus Therapeutics, Inc. The subsidiary is focused on realizing significant value for both companies, enhancing business focus, speed, and efficiency toward the realization of breakthrough I-O "living drugs" to advance cures for patients with cancer.
Oct 20, 2017 08:00 pm ET
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant
LEXINGTON, Mass., Oct. 20, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. The addition of QS-21 Stimulon helps improve the vaccine's effectiveness by boosting immune r
Oct 13, 2017 03:09 pm ET
GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada
LEXINGTON, Mass., Oct. 13, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization to GlaxoSmithKline's (GSK) shingles vaccine, Shingrix, that contains Agenus' proprietary immune adjuvant QS-21 Stimulon® adjuvant. The approval in Canada marks the first approval for Shingrix and the first approval of a vaccine containing QS-21 Stimulon.
Sep 19, 2017 08:00 am ET
Agenus to Present at Two Healthcare Investor Conferences In September
LEXINGTON, Mass., Sept. 19, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare investment conferences in September. The details for the conferences are:
Sep 13, 2017 04:53 pm ET
GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee recommendation for approval
LEXINGTON, Mass., Sept. 13, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that GlaxoSmithKline's (GSK) shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune adjuvant, QS-21 Stimulon®, was unanimously recommended for approval by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee.
Sep 13, 2017 04:49 pm ET
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
LONDON, Sept. 13, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix, for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.
Aug 03, 2017 09:50 am ET
Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass., Aug. 3, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the second quarter ended June 30, 2017.
Jul 27, 2017 09:50 am ET
Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow
LEXINGTON, Mass., July 27, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2017 financial results before the market opens on Thursday, August 3, 2017. Agenus executives will host a conference call at 11:00 a.m. ET the same day.
Jun 21, 2017 12:19 pm ET
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
LONDON, June 21, 2017 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today will be presenting new results from a clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or older, Shingrix (HZ/su), induces a strong immune response in older adults who have previously been vaccinated against shingles with the currently available live-attenuated zoster vaccine (ZVL). The results of the Zoster-048 study will be presented today at the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) meeting.
Jun 21, 2017 09:50 am ET
Agenus to Webcast Annual Meeting of Stockholders
LEXINGTON, Mass., June 21, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Wednesday, June 28, 2017. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
Jun 05, 2017 01:30 pm ET
Agenus' anti-CTLA-4 antibody shows strong safety and tolerability
LEXINGTON, Mass., June 5, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the results from an ongoing Phase 1 dose-escalation trial for its anti-CTLA-4 antibody, AGEN1884, in patients with advanced solid malignancies. The results were presented during a poster session at the 2017 American Society of Clinical Oncology (ASCO) held in Chicago, IL.
Jun 01, 2017 09:50 am ET
Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences
LEXINGTON, Mass., June 1, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the Company will present at the following conferences to be held in New York City, USA:
May 22, 2017 09:50 am ET
Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting
LEXINGTON, Mass., May 22, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that an abstract on its anti-CTLA-4 antibody, AGEN1884 was accepted for poster presentation. The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting will be held in Chicago, IL from June 2-6, 2017.
May 04, 2017 09:50 am ET
Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass., May 4, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the first quarter ended March 31, 2017.
Apr 27, 2017 09:50 am ET
Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow
LEXINGTON, Mass., April 27, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its first quarter 2017 financial results before the market opens on Thursday, May 4, 2017. Agenus executives will host a conference call at 11:00 a.m. ET the same day.
Apr 20, 2017 09:50 am ET
Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins
LEXINGTON, Mass., April 20, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034.
Apr 05, 2017 09:50 am ET
Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™
LEXINGTON, Mass., April 5, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1 clinical trial of AutoSynVax™ (ASV™), Agenus' neoantigen vaccine. Preclinical data presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting show ASV to be active and synergistic with checkpoint blockade.
Mar 30, 2017 07:45 am ET
Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies
LEXINGTON, Mass., March 30, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that it is reorganizing its business and operations to sharpen its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Agenus plans to close its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions across the organization. Additionally, Robert Stein, M.D., Ph.D., Presiden
Mar 24, 2017 09:50 am ET
Agenus to Participate at Two Upcoming Immuno-Oncology Conferences
LEXINGTON, Mass., March 24, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences:
Mar 09, 2017 08:50 am ET
Agenus Reports Fourth Quarter and Full Year 2016 Results
LEXINGTON, Mass., March 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2016.
Mar 07, 2017 08:50 am ET
Four Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting
LEXINGTON, Mass., March 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that four abstracts on its checkpoint antibodies and cancer vaccine candidates were accepted for poster presentation. The AACR 2017 Annual Meeting will be taking place in Washington, D.C. from April 1-5, 2017.
Mar 02, 2017 08:50 am ET
Agenus to Report Fourth Quarter and Year End 2016 Financial Results on March 9, 2017; Conference Call to Follow
LEXINGTON, Mass., March 2, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and year end 2016 financial results before the market opens on Thursday, March 9, 2017. Agenus executives will host a conference call at 11:00 a.m. ET the same day.
Jan 30, 2017 09:00 am ET
Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer
LEXINGTON, Mass., Jan. 30, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Jean-Marie Cuillerot, M.D. was appointed Chief Medical Officer (CMO). Dr. Cuillerot initially joined Agenus in 2016 as the Vice President and Global Head of Clinical Development.
Jan 17, 2017 09:00 am ET
Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine
LEXINGTON, Mass., Jan. 17, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a clinical trial collaboration with the National Cancer Institute (NCI). The double-blind, randomized controlled Phase 2 trial will evaluate the effect of Agenus' personalized autologous vaccine candidate, Prophage™ (HSPPC-96), in conjunction with Merck's pembrolizumab on the overall survival rate of patients with newly diagnosed glioblastoma (ndGBM). The trial will be conducted by the Brain Tumor Trials Co
Nov 30, 2016 08:50 am ET
Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors
LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, and in collaboration with, Incyte Corporation.
Nov 14, 2016 08:50 am ET
Agenus to Present at the Jefferies 2016 London Healthcare Conference
LEXINGTON, Mass., Nov. 14, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced that the Company will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16th at 9:20 a.m. GMT in London, UK.
Oct 27, 2016 09:50 am ET
Agenus Reports Third Quarter Financial Results and Recent Highlights
LEXINGTON, Mass., Oct. 27, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today provided an update on its progress and reported financial results for the third quarter ended September 30, 2016.
Oct 20, 2016 10:00 am ET
Agenus to Report Third Quarter 2016 Financial Results on October 27, 2016; Conference Call to Follow
LEXINGTON, Mass., Oct. 20, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN) will release its third quarter 2016 financial results before the market opens on Thursday, October 27, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.
Oct 18, 2016 09:50 am ET
Agenus Appoints James Gorman, M.D., Ph.D. as Vice President of Strategic Planning and Portfolio Management
LEXINGTON, Mass., Oct. 18, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators and cancer vaccines, today announced the appointment of James Gorman, M.D., Ph.D. as the Company's Vice President of Strategic Planning and Portfolio Management. Dr. Gorman has a wealth of industry experience in implementing innovative strategic initiatives, portfolio prioritization and corporate development.
Sep 06, 2016 09:50 am ET
Agenus to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
LEXINGTON, Mass., Sept. 6, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the Company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12th at 2:10 p.m. Eastern Time. The conference will take place at the Lotte New York Palace Hotel in New York City.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.